Mitochondrial Dynamin-Related Protein Drp1: a New Player in Cardio-oncology

Yali Deng1,2 · Doan T. M. Ngo3 · Jessica K. Holien1,4 · Jarmon G. Lees1,2 · Shiang Y. Lim1,2,5,6

Abstract
Purpose of Review This study is aimed at reviewing the recent progress in Drp1 inhibition as a novel approach for reducing doxorubicin-induced cardiotoxicity and for improving cancer treatment.
Recent Findings Anthracyclines (e.g. doxorubicin) are one of the most common and effective chemotherapeutic agents to treat a variety of cancers. However, the clinical usage of doxorubicin has been hampered by its severe cardiotoxic side effects leading to heart failure. Mitochondrial dysfunction is one of the major aetiologies of doxorubicin-induced cardiotoxicity. The morphology of mitochondria is highly dynamic, governed by two opposing processes known as fusion and fission, collectively known as mitochondrial dynamics. An imbalance in mitochondrial dynamics is often reported in tumourigenesis which can lead to adaptive and acquired resistance to chemotherapy. Drp1 is a key mitochondrial fission regulator, and emerging evidence has demonstrated that Drp1-mediated mitochondrial fission is upregulated in both cancer cells to their survival advantage and injured heart tissue in the setting of doxorubicin-induced cardiotoxicity.
Summary Effective treatment to prevent and mitigate doxorubicin-induced cardiotoxicity is currently not available. Recent advances in cardio-oncology have highlighted that Drp1 inhibition holds great potential as a targeted mitochondrial therapy for doxorubicin-induced cardiotoxicity.

Keywords Dynamin-related protein · Mitochondria · Doxorubicin · Cardiomyopathy · Cancer

Introduction
The global cancer burden is projected to reach 28.4 million cases in 2040, a 47% rise from 2020 [1]. With recent medical advancements in early detection and effective cancer therapies, the number of long-term cancer survivors is estimated to surpass 22.1 million by 2030 in the USA [2]. The 10-year survival rate of the twenty most common malignancies sits at approximately 50% and is greater than 80% in melanoma, lymphoma, breast and uterine cancers in developed countries [3]. Paradoxically, the improved prognosis for cancer patients is accompanied by a growing population with secondary cardiac complications. Doxorubicin, which belongs to a class of antibiotic anthracyclines, is a potent cytotoxic chemotherapeutic drug widely prescribed for cancer treatment [4]. Doxorubicin is commonly used to treat children and adults with solid tumours (e.g. breast and ovarian cancer) and haematological malignancies (e.g. leukaemia and lymphoma) [5]. Unfortunately, the clinical usage of doxorubicin is associated with dose-dependent and cumulative cardiotoxicity that may lead to
congestive heart failure [6]. It is estimated that half of the children diagnosed with cancer receive anthracyclines as part of their cancer therapy [7]. Of note, the prevalence of doxorubicin-induced cardiac dysfunction has reached 30% of adult survivors of childhood cancer in western populations [8, 9].

Although the advent of more targeted cancer therapies has reduced the usage of doxorubicin as the first-line treatment, doxorubicin remains the mainstay treatment against cancers that are refractory to those new treatment and have no druggable targets [10, 11]. Doxorubicin exerts its anti-tumour effects predominately through DNA damage, disruption of mitochondrial function and production of reactive oxygen species (ROS), which ultimately cause cell death [12–15]. Despite its effective anti-tumour effects, the clinical utility of doxorubicin has been restricted by its tendency to cause cardiovascular complications including left ventricular systolic dysfunction and heart failure [6, 16]. The incidence of acute doxorubicin-induced cardiotoxicity is about 11%, usually occurring within days to months after administration [17]. Common acute manifestations include arrhythmia and left ventricular dysfunction [6, 18, 19]. Chronic doxorubicin-induced cardiomyopathy usually occurs within a year, with an overall incidence of 9%, but it may also manifest in cancer survivors up to 30 years after their last treatment regimen. Chronic doxorubicin-induced cardiomyopathy is progressive and irreversible, characterised by a significant reduction in left ventricular fractional shortening and ejection fraction, which may lead to heart failure [17, 20–22]. Notably, the risk of developing congestive heart failure is primarily related to the cumulative dose, increasing from 5% when the dose of doxorubicin is 400 mg/m² to 26% at 550 mg/m² and 48% when the dose exceeds 700 mg/m² [23]. Devastatingly, patients who develop congestive heart failure often have a poor prognosis, with a 2-year mortality rate of about 50% [24].

The difference in the time of onset of doxorubicin-induced cardiomyopathy may be attributed to the genetic polymorphisms of individuals that have altered antioxidant capacity, membrane permeability and metabolisms, which render certain individuals more susceptible to cardiac damage. For example, a genetic disorder known as hemochromatosis that causes iron overload is likely to increase the susceptibility of an individual to doxorubicin-induced cardiotoxicity [25]. Additionally, the basal mitochondrial capacity and mitochondrial DNA fitness in cardiomyocytes may also determine the severity of cardiac dysfunction and their resistance to doxorubicin-induced cardiomyopathy [26–28]. Other risk factors that may lend predilection for doxorubicin-induced cardiomyopathy include those that are treatment associated (concomitant cardiotoxic therapies such as monoclonal antibody trastuzumab and mediastinal radiotherapy) and patient related (sex, age, existing chronic conditions such as cardiovascular disease, hypertension, liver disease and diabetes mellitus) [29–31].

The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are complicated and multifaceted, as reviewed extensively elsewhere [32]. Despite extensive research over the past decades which has suggested its putative mechanisms, the precise molecular signalling pathways associated with the cardiotoxic effects of doxorubicin remain elusive [32]. The majority of studies have concluded cardiomyocyte death as the principal mechanism [33]. The main causes of cardiomyocyte death include death receptor activation, oxidative stress, calcium dysregulation, mitochondrial dysfunction and DNA damage [31, 34–37].

**Current Strategies to Treat Doxorubicin-Induced Cardiotoxicity**

Many pharmacotherapies have been investigated for their potential to protect the heart against doxorubicin-induced cardiotoxicity. Unfortunately, effective strategies to prevent or remediate doxorubicin-induced cardiomyopathy are yet to be established in clinical practice [38]. It is evident that the anti-cancer effects of doxorubicin overlap with its cardiotoxic effects; hence, there is a possibility that cardioprotective agents could also reduce the oncological efficacy of doxorubicin by acting through the same mechanisms.

The current clinical practice guideline for patients with established cardiomyopathy and heart failure includes pharmacotherapies with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, β-adrenergic blockers, combined angiotensin receptor and neprilysin inhibitors, mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors [39, 40]. Although these medications were not developed specifically for doxorubicin-induced cardiomyopathy, some have been proven to be effective for heart failure due to doxorubicin and have been clinically implemented as a standard guideline-directed medical therapy for patients who have developed cardiomyopathy and heart failure after doxorubicin treatment [39, 40]. For example, co-administration of ACE inhibitors such as enalapril with doxorubicin has been shown to reduce doxorubicin-induced cardiac dysfunction through the preservation of mitochondrial respiratory efficiency and reduction in free radical production [41, 42]. Treatment with non-selective β-adrenergic blockers such as propranolol and carvedilol has also shown to improve cardiac function and reduce cardiac injury in the setting of doxorubicin-induced cardiotoxicity [43–47]. Despite these positive findings, there is limited evidence available regarding their cardioprotective mechanisms in the setting of doxorubicin-induced cardiomyopathy and whether these protective agents might interfere with the anti-cancer effects of doxorubicin.
Other agents targeting mitochondrial processes such as antioxidants have also shown to exert cardioprotective effects by detoxifying excess ROS and reducing apoptosis in a pre-clinical study [48]. Yet the cardioprotective effect of antioxidants did not translate into clinical benefits in terms of preventing or reversing cardiac dysfunction and heart failure in patients receiving doxorubicin [49, 50]. To date, the only Food and Drug Administration–approved cardioprotective drug against doxorubicin-induced cardiotoxicity is dexrazoxane, an iron-chelator with an additional ability to act as a protective drug against doxorubicin-induced cardiotoxicity is only Food and Drug Administration–approved cardioprotective drug against doxorubicin-induced cardiotoxicity is dexrazoxane, an iron-chelator with an additional ability to inhibit topoisomerase II-beta in cardiomyocytes [51]. However, the clinical use of dexrazoxane is limited to patients with advanced breast cancer who are receiving doxorubicin at a cumulative dose of over 300 mg/m\(^2\) due to the risk of developing myelosuppression and secondary tumours that could interfere with the anti-cancer activity of doxorubicin [4, 52, 53]. It is important to note that recent randomised controlled trials reported that dexrazoxane did not compromise anti-tumour efficacy of doxorubicin or increase the risk of developing secondary tumours in children and adolescents [54, 55].

Given the limited success of existing therapeutic agents in preventing or treating doxorubicin-induced cardiotoxicity, finding other approaches that could effectively mitigate cardiotoxicity without compromising the effectiveness of doxorubicin is an important unmet medical need.

**Mitochondrial Dynamics**

Mitochondria are a major cellular target of doxorubicin. Mitochondrial damage is a prominent feature of doxorubicin-induced apoptosis. Mitochondrial fusion and fission processes are known to play an important role in regulating mitochondrial morphology and function such as mitochondrial metabolism and bioenergetics, intracellular ROS production and calcium signalling [56]. Mitochondria exist in a spectrum of shapes and sizes, ranging from small fragments of spheres or rods (fission) to elongated tubules and interconnected networks (fusion) [57]. Mitochondrial fusion and fission processes are tightly regulated by a group of highly conserved dynamin superfamilies known as large GTPases, recognised for their intracellular membrane remodelling activities through their self-assembly and GTP hydrolysing capabilities [58]. These mechanochemical GTPase proteins include mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy 1 (Opa1), which enhance mitochondrial fission. In contrast, mitochondrial fission is mediated by dynamin-related protein 1 (Drp1), mitochondrial fission 1 protein (Fis1), mitochondrial fission factor (Mff) and mitochondrial dynamic protein of 49 and 51 kDa (Mid49/51) in mammals [57, 59] (Fig. 1).

A concerted balance of mitochondrial fission and fusion is important for preserving mitochondrial morphology, which in turn influences the physiological functions of a cell. Mitochondrial fission participates in (1) inheritance and compartmentalization of mitochondria via a cytoskeletal-mediated transmission [62], (4) regulation of calcium homeostasis [63], (5) programmed cell death through the release of pro-apoptotic factors [64] and (6) G2/M cell cycle progression during mitosis [65].

On the other hand, mitochondrial fusion is an important process to maintain a healthy mitochondrial population by preventing the accumulation of defective mitochondria in a cell population. Mitochondrial fusion defends cells from the deleterious effects of mitochondrial deoxyribonucleic acid (DNA) mutations by enabling the exchange of genetic content with impaired mitochondria through a process known as functional complementation [66, 67]. Moreover, fused mitochondrial networks are required for maximal ATP synthesis by stimulating oxidative phosphorylation in energetically active cells or when cells respond to stress stimuli such as nutrient deprivation to preserve energy [68, 69].

**The Role of Drp1 in Cancer**

Dysregulation of mitochondrial dynamics is often linked to cancer tumourigenesis and progression, as reviewed comprehensively elsewhere [70, 71]. Specifically, the upregulation of mitochondrial Drp1 with concomitant downregulation of Mfn2 has been shown to promote tumourigenesis in many cancers including lung, gastric, breast, glioma, colon, ovarian, pancreatic and melanoma [72]. In most instances, Drp1-mediated mitochondrial fission promotes replication, invasion and migration, and drug tolerance in tumour cells thereby enhancing tumour growth [73]. Thus, inhibition of Drp1 has been reported to exert anti-tumour effects shown to enhance apoptosis and reduce proliferation of tumour cells [74–77].

A putative small molecule inhibitor of Drp1, Mdivi-1, has been widely employed to study the pathophysiological roles of Drp1-mediated mitochondrial fission. Mdivi-1 is a quinazolinone derivative and a reversible allosteric inhibitor of Drp1 discovered from a chemical library in a yeast-based assay [78]. By inhibiting the GTPase activity of Drp1, Mdivi-1 has been found to reduce Drp1 self-assembly on the mitochondrial outer membranes and mitochondrial fission in mammalian cells [78, 79]. Mdivi-1 exerts cytotoxic effects in hyper-proliferative cancer cells by inducing death receptor–mediated apoptosis and inhibiting cell cycle progression [80–82]. In breast cancer cells, Mdivi-1 significantly reduced metabolic reprogramming, mitophagy and...
Similarly, short interference ribonucleic acid (siRNA)–mediated Drp1 knockdown or pharmacological inhibition of Drp1 using Mdivi-1 reduced breast cancer cell metastasis and invasiveness [76, 84].

A major clinical challenge in cancer therapy is addressing chemoresistance, which promotes cancer recurrence and metastasis and hampers the clinical outcomes of cancer patients. Drp1 inhibition, either via gene silencing of Drp1 or pharmacologically using Mdivi-1, has been shown to sensitize multiple cancer cell lines to the cytotoxic effects of chemotherapeutic agents. For example, Mdivi-1 or siRNA against Drp1 enhanced cisplatin-induced apoptosis in breast carcinoma (MDA-MB-231), renal cancer cells (Caki-1), lung carcinoma (A549 and A1299), colon carcinoma (HCT116) and ovarian carcinoma (SKOV3, PA1 and A2780) [80, 85, 86]. Similarly, treatment with Mdivi-1 has been shown to enhance cisplatin-induced apoptosis in hepatocellular carcinomas by suppressing Drp1-mediated mitophagy [87]. Drp1 inhibition also sensitizes malignant melanoma, lung cancer and osteosarcoma cells to tumour necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated apoptosis through a caspase-dependent pathway [88]. Courtois and colleagues reported that Mdivi-1 can chemosensitize pancreatic ductal adenocarcinomas to the chemotherapeutic agent gemcitabine by inhibiting mitochondrial fission and inducing mitochondrial dysfunction that led to the accumulation of defective mitochondria and ultimately cell death [89]. Treatment with Mdivi-1 has also been demonstrated

---

**Fig. 1** The role of Drp1 upregulation in doxorubicin-induced cardiotoxicity. Mitochondrial morphology is governed by fusion and fission proteins, which in turn affects mitochondrial functions. Pro-fusion (Mfn1&2, Opa1) and pro-fission (Drp1, Fis1, Mff and Mid49/51) proteins are core mediators in fine-tuning mitochondrial morphology and function. Perturbation in the fission and fusion processes can shift the mitochondrial dynamics towards mitochondrial fragmentation (fission) or mitochondrial elongation and formation of a hyperfused network (fusion). Doxorubicin upregulates Drp1 expression which tilts the mitochondrial dynamic balance towards fission to trigger various downstream effects that ultimately lead to cardiomyocyte apoptosis and cardiac injury. The Drp1 inhibitor is a promising pharmacological agent that inhibits the excessive doxorubicin-mediated mitochondrial fission and attenuates its cardiotoxic effects. Mfn1 mitofusin 1, Mfn2 mitofusin 2, Opa1 optic atrophy 1, Drp1 dynamin-related protein 1, Fis1 mitochondrial fission protein 1, Mff mitochondrial fission factor, Mid49 mitochondrial dynamics protein 49 kDa, Mid51 mitochondrial dynamics protein 51 kDa, DOX doxorubicin, mtDNA mitochondrial deoxyribonucleic acid, MPTP mitochondrial permeability transition pore, ROS reactive oxygen species.
to augment Taxol cytotoxicity in breast carcinoma MDA-MB-231 cells by inducing spindle abnormalities [90].

In contrast, some studies have reported a pro-tumorigenic effect of Drp1 inhibition. Li et al. showed that suppression of mitochondrial translocation of Drp1 through its phosphorylation at serine residue 637 promoted hepatocellular cancer cell metabolic reprogramming and survival [91]. In another study, inhibition of Drp1-dependent mitochondrial fission via siRNA against Drp1 or Mdivi-1 compromised the cytotoxic effect of cisplatin in MDA-MB-231 breast cancer cells via an inhibition of cisplatin-induced intracellular ROS production and recovery of mitochondrial membrane potential [92]. Furthermore, Tang and colleagues have demonstrated that IR-783, a heptamethine cyanine dye commonly used for imaging cancer cells, exhibits anti-cancer properties by increasing Drp1-mediated mitochondrial fission in MDA-MB-231 breast cancers [93]. Knockdown of Drp1 markedly blocked IR-783-induced mitochondrial fission, loss of mitochondrial membrane potential, ATP depletion, mitochondrial permeability transition pore opening and apoptosis. Additionally, IR-783 also induced apoptosis and inhibited tumour growth in MDA-MB-231 in vivo in a xenograft model [93].

Mitochondria provide more than 90% of the ATP required by cardiomyocytes to support normal cardiac contractility, and mitochondrial fusion and fission proteins play critical roles in cardiac homeostasis [95]. Doxorubicin promotes cardiomyocyte apoptosis by altering mitochondrial structure and function, which is associated with a disruption in mitochondrial redox homeostasis and dysregulated mitochondrial dynamics. Mechanistically, doxorubicin induces excessive mitochondrial ROS production, disrupts mitochondrial membrane structure and depolarises the mitochondrial membrane potential, leading to cell death [96]. Moreover, doxorubicin has been shown to cause excessive mitochondrial fragmentation in cardiomyocytes through the increased phosphorylation of Drp1 at serine 616 and decreased expression of the Opa1 protein, which accelerates mitochondrial-dependent apoptosis [97]. This positions mitochondrial fusion and fission proteins as promising therapeutic targets for protection against doxorubicin-induced cardiotoxicity by restoring the balance of mitochondrial dynamics [98] (Fig. 1).

Recent studies have also suggested a possible role of endoplasmic reticulum stress in exacerbating the cardiotoxic effects of doxorubicin. Bagchi and colleagues have shown that doxorubicin-induced oxidative stress activated the opening of the mitochondrial permeability transition pore and increased pro-apoptotic Bax protein expression in primary rat cardiomyocytes [99]. This in turn enhanced the protein expression of endoplasmic reticulum chaperone proteins and DNA damage-inducible transcriptor-3 in the endoplasmic reticulum, leading to endoplasmic reticulum stress and apoptosis [99]. Notably, Drp1-mediated fission also plays a role in ER stress by promoting remodelling of endoplasmic reticulum microdomains to constrict mitochondria and promote/drive mitochondrial fission [100]. Pharmacological Drp1 inhibition using Mdivi-1 effectively suppresses endoplasmic reticulum remodelling–driven mitochondrial fission and autophagy in cardiometabolic proteostasis [100]. Altogether, targeting dysregulated Drp1-dependent mitochondrial fission may provide a novel approach to reduce doxorubicin-induced cardiotoxicity. Indeed, pre-clinical studies have demonstrated the cardioprotective effect of Drp1 inhibition in doxorubicin-induced cardiotoxicity in both in vitro and in vivo settings (Table 1).

A recent study by Catanaro and colleagues has demonstrated that Drp1 knockdown attenuated doxorubicin-induced cardiac injury in H9c2 cardiomyoblasts and mice in vivo, which was associated with reduced doxorubicin-induced mitochondrial fission and cell death [102]. This finding is in keeping with an earlier study that reported a cardioprotective effect of siRNA-mediated Drp1 knockdown in neonatal rat cardiomyocytes subjected to doxorubicin-induced toxicity [101]. Using a pharmacological approach, Gharanei and colleagues have demonstrated that inhibition of Drp1 with Mdivi-1 exerted a cardioprotective effect in Langendorff-perfused rat hearts subjected to doxorubicin-induced cardiac injury by reducing mitochondrial fission and cardiomyocyte apoptosis [103]. Similarly, Mdivi-1 effectively reduced doxorubicin-induced cardiomyocyte

The Role of Drp1 in Doxorubicin-Induced Cardiotoxicity

Mitochondria provide more than 90% of the ATP required by cardiomyocytes to support normal cardiac contractility, and mitochondrial fusion and fission proteins play critical roles in cardiac homeostasis [95]. Doxorubicin promotes cardiomyocyte apoptosis by altering mitochondrial structure and function, which is associated with a disruption in mitochondrial redox homeostasis and dysregulated mitochondrial dynamics. Mechanistically, doxorubicin induces excessive mitochondrial ROS production, disrupts mitochondrial membrane structure and depolarises the mitochondrial membrane potential, leading to cell death [96]. Moreover, doxorubicin has been shown to cause excessive mitochondrial fragmentation in cardiomyocytes through the increased phosphorylation of Drp1 at serine 616 and decreased expression of the Opa1 protein, which accelerates mitochondrial-dependent apoptosis [97]. This positions mitochondrial fusion and fission proteins as promising therapeutic targets for protection against doxorubicin-induced cardiotoxicity by restoring the balance of mitochondrial dynamics [98] (Fig. 1).

Recent studies have also suggested a possible role of endoplasmic reticulum stress in exacerbating the cardiotoxic effects of doxorubicin. Bagchi and colleagues have shown that doxorubicin-induced oxidative stress activated the opening of the mitochondrial permeability transition pore and increased pro-apoptotic Bax protein expression in primary rat cardiomyocytes [99]. This in turn enhanced the protein expression of endoplasmic reticulum chaperone proteins and DNA damage-inducible transcriptor-3 in the endoplasmic reticulum, leading to endoplasmic reticulum stress and apoptosis [99]. Notably, Drp1-mediated fission also plays a role in ER stress by promoting remodelling of endoplasmic reticulum microdomains to constrict mitochondria and promote/drive mitochondrial fission [100]. Pharmacological Drp1 inhibition using Mdivi-1 effectively suppresses endoplasmic reticulum remodelling–driven mitochondrial fission and autophagy in cardiometabolic proteostasis [100]. Altogether, targeting dysregulated Drp1-dependent mitochondrial fission may provide a novel approach to reduce doxorubicin-induced cardiotoxicity. Indeed, pre-clinical studies have demonstrated the cardioprotective effect of Drp1 inhibition in doxorubicin-induced cardiotoxicity in both in vitro and in vivo settings (Table 1).

A recent study by Catanaro and colleagues has demonstrated that Drp1 knockdown attenuated doxorubicin-induced cardiac injury in H9c2 cardiomyoblasts and mice in vivo, which was associated with reduced doxorubicin-induced mitochondrial fission and cell death [102]. This finding is in keeping with an earlier study that reported a cardioprotective effect of siRNA-mediated Drp1 knockdown in neonatal rat cardiomyocytes subjected to doxorubicin-induced toxicity [101]. Using a pharmacological approach, Gharanei and colleagues have demonstrated that inhibition of Drp1 with Mdivi-1 exerted a cardioprotective effect in Langendorff-perfused rat hearts subjected to doxorubicin-induced cardiac injury by reducing mitochondrial fission and cardiomyocyte apoptosis [103]. Similarly, Mdivi-1 effectively reduced doxorubicin-induced cardiomyocyte

© Springer
Importantly, the cardioprotective effect of liensinine was mediated by the Rab7-Erk-Drp1 signalling axis [110]. Liensinine maintained cell survival via decreasing Rab7 level which led to a reduction in ERK and Drp1 protein phosphorylation levels. Consequently, liensinine reversed mitochondrial fragmentation and ultimately inhibited mitochondrial fission–mediated cell death.

The traditional Chinese herbal medicine, Shenmai, has also been used to demonstrate cardioprotection against doxorubicin-induced cardiotoxicity via maintaining mitochondrial homeostasis. Treatment with Shenmai suppressed excessive doxorubicin-induced mitochondrial fission by increasing the ratio of fusion protein L-Opa1 to S-Opa1 and phosphorylation of Drp1 at serine 637 residue. Consequently, treatment with Shenmai rescued H9c2 cardiomyoblasts from doxorubicin-induced apoptosis, excessive mitochondrial ROS production and loss of mitochondrial membrane potential [97]. More recently, Klotho, an anti-ageing protein, was found to suppress doxorubicin-induced apoptosis in neonatal rat ventricular cardiomyocytes and H9c2 cardiomyoblasts. In doxorubicin-treated mice, Klotho effectively reduced cardiac cell death and improved cardiac function through attenuation of Drp1 Ser616 phosphorylation [105]. In addition, a neuraminidase 1 inhibitor called oseltamivir has also been reported to exert cardioprotective effects against doxorubicin-induced cardiotoxicity via suppressing Drp1-dependent mitophagy. In vivo, oseltamivir

### Table 1  The role of Drp1 in anthracycline-induced cardiotoxicity

| Approaches                | Study models                                                                 | Outcomes                                                                 |
|---------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| siRNA of Drp1 [101]       | Neonatal rat cardiomyocytes treated with 2 µM of doxorubicin for 12 h        | Reduced doxorubicin-induced mitochondrial fragmentation, cytochrome c release, loss of mitochondrial membrane potential and cell death |
| siRNA of Drp1 [102]       | H9c2 cardiac myoblast cells treated with 750 nM of doxorubicin for 24 h     | Attenuated doxorubicin-induced mitochondrial fragmentation, mitophagy flux and cell death |
|                           | Ventricular cardiomyocytes isolated from adult mice treated with 3 µM of doxorubicin for 24 h | Reduced doxorubicin-induced mitochondrial fragmentation |
| Drp1 knockout mice [102]  | Drp1 heterozygous knockout mice received a single dose of doxorubicin (15 mg/kg) via intraperitoneal injection for 3 days | Protected against doxorubicin-induced cardiac injury. Reduced doxorubicin-induced mitochondrial fragmentation, oxidative stress and lipid peroxidation |
| Mdivi-1 [103]             | Ex vivo rat heart subjected to acute ischaemia–reperfusion injury and treated with 1 µM doxorubicin ± 1 µM of Mdivi-1, given at reperfusion for 2 h | Protected against doxorubicin-induced myocardial dysfunction and infarction |
|                           | Primary adult rat cardiomyocytes treated with 1 µM of doxorubicin ± 1 µM of Mdivi-1 for 4 h | Reduced doxorubicin-induced mitochondrial depolarisation and hyper-contracture of cardiomyocytes |
| Mdivi-1 [104]             | H9c2 rat cardiomyoblasts pre-treated with 1 µM of Mdivi-1 for 30 min and then incubated with 5 µM of doxorubicin for 24 h | Reduced doxorubicin-induced mitochondrial fragmentation and cell death |
| Mdivi-1 [105]             | Neonatal rat ventricular cardiomyocytes were pre-treated with 1 µM of Mdivi-1 for 30 min ± 5 µM of doxorubicin for 24 h | Prevented doxorubicin-induced mitochondrial fission and apoptosis |
| Mdivi-1 [106]             | H9c2 cardiomyocytes treated with 1 µM of doxorubicin ± Mdivi-1*              | Attenuated doxorubicin-induced apoptosis, upregulation of Drp1 expression and autophagic activities |

*Concentration of Mdivi-1 was not reported in the study

siRNA short interference ribonucleic acid, *Mdivi-1* mitochondrial division inhibitor 1, *Drp1* dynamin-related protein 1
improved doxorubicin-induced cardiac dysfunction in male Sprague–Dawley rats. In vitro, oseltamivir suppressed myocardial apoptosis through inhibition of Drp1–mediated excessive fission and mitophagy in both doxorubicin-treated rats and H9c2 cardiomyoblasts [106]. Taken together, various pharmacological approaches have underscored the importance of Drp1 inhibition as a potential mechanism to protect cardiomyocytes against doxorubicin-induced cardiotoxicity.

Conclusion and Future Perspectives

One of the key challenges when choosing a cardioprotective agent to prevent or mitigate doxorubicin-induced cardiotoxicity is the parallel evaluation of the anti-cancer activity of doxorubicin to ensure that its oncological efficacy is not compromised. Notably, Drp1–mediated mitochondrial fission activity is upregulated in most cancer cells conferring a survival advantage and in heart tissue as a key contributor to doxorubicin-induced cardiotoxicity. Current pre-clinical animal and cell culture studies have suggested that Drp1 inhibition is a promising approach for protecting the heart against doxorubicin-induced injury without compromising the anti-cancer properties of doxorubicin in treating various types of cancer. Moreover, Drp1 inhibition appears to exert anti-cancer effects in some cancer cells [70, 71] and might also have synergistic anti-cancer effects with doxorubicin and other chemotherapeutic agents in cancers where dysregulation of mitochondrial dynamics occurs; however, this remains to be determined.

To date, the cardioprotective effects of Drp1 inhibition in doxorubicin-induced cardiotoxicity have only been demonstrated in limited pre-clinical studies using either an in vivo animal model or in vitro primary rodent cardiomyocytes and H9c2 rat cardiomyoblasts (Table 1). With the advent of stem cell technology, human cardiomyocytes derived from induced pluripotent stem cells (iPSC) generated from individual somatic cells represent a superior pre-clinical human model for disease modelling and development of personalised treatments. Indeed, many studies have successfully employed human iPSC–derived cardiomyocytes to model doxorubicin-induced cardiotoxicity [111–115].

Cardiomyocyte death is well known as the primary cause of doxorubicin-induced cardiomyopathy [116, 117]. Since the myocardium is a heterocellular tissue comprised of both cardiomyocytes and non-cardiomyocytes such as cardiac fibroblasts, endothelial cells, smooth muscle cells and autonomic neurons, there is a potential involvement of non-cardiomyocytes in doxorubicin-induced cardiotoxicity. Indeed, recent studies have reported non-cardiomyocytes as cytotoxic targets of doxorubicin [118]. Increased oxidative stress triggered by doxorubicin mediates a plethora of cellular signalling pathways including cardiac hypertrophy, fibrosis, impaired angiogenesis, cell senescence and death [118]. Cardiac fibrosis is triggered by necrotic and apoptotic cell damage as well as pathological remodelling in response to excessive ROS production. Studies have reported a role for doxorubicin-induced cardiotoxicity in triggering apoptosis, a pro-fibrotic phenotype and senescence in mouse and rat cardiac fibroblasts [119–121]. Additionally, endothelial cells are also implicated in doxorubicin-induced oxidative stress [122, 123], which is correlated with endothelial cell apoptosis and reduced endothelial plasticity [124]. Treatment with doxorubicin has also been shown to promote premature senescence in smooth muscle cells isolated from the human aorta, characterised by excessive ROS generation, abnormal morphology, accumulation of DNA damage foci and increased activity of senescence associated-β-galactosidase [125]. Given the complexity of the underlying pathogenesis of doxorubicin-induced cardiomyopathy, a better model such as the use of a 3-dimensional multicellular cardiac organoid consisting of both cardiomyocytes and non-cardiomyocytes is needed to better dissect the mechanisms underlying doxorubicin-induced cardiomyopathy [126]. In addition, disease models that better recapitulate the cellular heterogeneity of the native heart will help to further elucidate mechanisms underlying the cardioprotective effects of various pharmacotherapies and facilitate novel drug development.

Pharmacological inhibition of Drp1 has been demonstrated to be effective at attenuating doxorubicin-induced cardiotoxicity by reducing cardiomyocyte death in pre-clinical animal and cell culture studies (Table 1). Among all Drp1 inhibitors, Mdivi-1 is the most extensively studied Drp1 inhibitor in pre-clinical settings. However, recent evidence has reported off-target effects of Mdivi-1, including the inhibition of mitochondrial complex I [127]. While Mdivi-1 may continue to be a useful research tool, its clinical utility will be restricted due to its unfavourable off-target effects, low potency and poor water solubility [78, 109]. Other available Drp1 inhibitors include P110 (peptide inhibitor that inhibits the interaction between Drp1 and Fis1) and Dynasore (a non-specific inhibitor of dynasmins). P110 improved cell function and mitochondrial dynamics in pre-clinical models of myocardial ischemia–reperfusion injury and neurodegenerative diseases [128, 129]. Dynasore has shown to promote apoptosis and reduce cell proliferation in A549 lung cancer cells [130, 131]. On the other hand, Dynasore exerted cardioprotective effects by improving left ventricular end-diastolic pressure and increasing the survival rate of cardiomyocytes upon ischemia–reperfusion injury in mice [132].

While existing Drp1 inhibitors have exhibited promising therapeutic effects in pre-clinical models, evidence supporting their specificity and selectivity to the human Drp1 GTPase binding site is lacking. The cardio-oncology field requires better tool compounds to understand the therapeutic
potential of Drp1-mediated fission inhibition in doxorubicin-induced cardiomyopathy. Recently, two novel Drp1 inhibitors, Drpitor1 and Drpitor1α, have been discovered to be more potent and specific than Mdivi-1 in inhibiting the GTPase activity of Drp1 [133]. Drpitor1 and Drpitor1α have also displayed anti-cancer effects by reducing cell proliferation and inducing apoptosis in lung cancer cells while conferring cardioprotective effects against ischemia–reperfusion injury in rodent models [133]. Further studies are required to validate the effectiveness of Drpitors in inhibiting human Drp1 GTPase and its therapeutic potential in pre-clinical models. Importantly, the benefits of Drp1 inhibition in humans are currently unknown, and future clinical trials are needed to evaluate the safety and efficacy of Drp1 inhibitors in clinical settings. In summary, Drp1 inhibition holds potential in translating a targeted mitochondrial therapy for doxorubicin-induced cardiotoxicity into clinical reality.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions This work was supported by grants from the Stafford Fox Medical Research Foundation, CASS Foundation, and St Vincent’s Hospital Research Endowment Fund. We would like to thank the infrastructure funding from the Victorian Government (Australia) Operational Infrastructure Support Scheme to St Vincent’s Institute of Medical Research. Y.D. is supported by University of Melbourne MDHS Trust Scholarships and Australian Government Research Training Program Scholarship.

Declarations

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics. 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

3. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Marinje C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannessen TB, Adolfsen J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38. https://doi.org/10.1016/s0140-6736(10)62231-3.

4. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protocents. J Clin Oncol. 2009;27(1):127–45. https://doi.org/10.1001/jco.2008.17.2627.

5. Veipongpa S, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938–45. https://doi.org/10.1016/j.jacc.2014.06.1167.

6. Alexandre J, Cautela J, Ederys H, Damaj GL, Salemi J, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403. https://doi.org/10.1161/jaha.120.018403.

7. van Dalen EC, Raphael MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev 2014; (9):Cd006647. https://doi.org/10.1002/14651858.CD006647.pub4.

8. Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, Griffin BP, Grimm RA, Thomas J, Phelan D, Collier P, Krull KR, Mulrooney DA, Green DM, Hudson MM, Robison LL, Plana JC. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65(23):2511–22. https://doi.org/10.1016/j.jacc.2015.04.013.

9. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36. https://doi.org/10.1016/s1470-2045(14)70409-7.

10. Cardoso F, Senkus E, Costa A, Papadopoulou E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Giaccone G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston S, Kaufman B, Koppikar S, Kroep IE, Mayer M, Nakigudde G, Oferrens BL, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC. Recommendations for cardiomyopathy surveillance in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65(23):2511–22. https://doi.org/10.1016/j.jacc.2015.04.013.

11. Anderson GR, Wardell SE, Cakir M, Yap C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP, Wood KC. Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. Nat Commun. 2018;9(1):1677. https://doi.org/10.1038/s41467-018-04033-x.

12. Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin–DNA adducts. IUBMB Life. 2005;57(2):73–81. https://doi.org/10.1080/15216540500079093.
13. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–33. https://doi.org/10.1016/j.chembiol.2010.04.012.

14. Jung K, Reszka R. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev. 2001;49(1–2):87–105. https://doi.org/10.1016/s0169-409x(01)00128-4.

15. Stěrba M, Popelová O, Vávrová A, Jirkovský E, Kováříková P, Geršl V, Šimůnek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18(8):899–929. https://doi.org/10.1089/ars.2012.4795.

16. Jeyaprakash P, Sangha S, Ellenberger K, Sivapathan S, Pathan F, Negishi K. Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: a systematic review and meta-analysis of placebo arms from randomized controlled trials. J Am Heart Assoc. 2021;10(6):e018802. https://doi.org/10.1161/jaha.120.018802.

17. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigiliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/circulationaha.114.013777.

18. Nishi M, Wang PY, Hwang PM. Cardiotoxicity of cancer treatments: focus on anthracycline cardiomyopathy. Arterioscler Thromb Vase Biol. 2021;41(11):2646–60. https://doi.org/10.1161/atvbaha.121.316697.

19. Fraley C, Milgrom SA, Kondapalli L, Taylor MRG, Mestrioni L, Miyamoto SD. Mechanisms and insights for the development of heart failure associated with cancer therapy. Children (Basel). 2021;8(9):829. https://doi.org/10.3390/children8090829.

20. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mithy P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. https://doi.org/10.1136/bmj.b4606.

21. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Gainane J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Elker GM, Thompson RE, Hare JM, Hruban RH, Clemetson NJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vallery RL, Andrews NC, Santos MM. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood. 2003;102(7):2574–80. https://doi.org/10.1182/blood-2003-03-0869.

22. Yue P, Jing S, Liu L, Ma F, Zhang Y, Wang C, Duan H, Zhou K, Hua Y, Wu G, Li Y. Association between mitochondrial DNA copy number and cardiovascular disease: current evidence based on a systematic review and meta-analysis. PLoS ONE. 2018;13(11):e0206003. https://doi.org/10.1371/journal.pone.0206003.

23. Pereira CV, Oliveira PJ, Will Y, Nadanaciva S. Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms. Toxicol Appl Pharmacol. 2012;264(2):167–81. https://doi.org/10.1016/j.taap.2012.07.030.

24. Foote K, Reinhold J, Yu EPK, Figg NL, Finigan A, Murphy MP, Bennett MR. Restoring mitochondrial DNA copy number preserves mitochondrial function and delays vascular aging in mice. Aging Cell. 2018;17(4):e12773. https://doi.org/10.1111/acel.12773.

25. Bhagat A, Kleinerman ES. Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181–92. https://doi.org/10.1007/978-3-030-43032-0_15.

26. Wallace KB, Sardao VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126(7):926–41. https://doi.org/10.1161/circresaha.119.314681.

27. Octavia Y, Tocchetti CG, Gabrielsson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–25. https://doi.org/10.1016/j.yjmcc.2012.03.006.

28. Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochem Biophys Acta. 2016;1863(7 Pt B):1916–25. https://doi.org/10.1016/j.bbapac.2016.01.021.

29. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz). 2009;57(6):435–45. https://doi.org/10.1007/s00005-009-051-8.

30. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735. https://doi.org/10.1038/srep44735.

31. Ichikawa Y, Ghanevar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasak RK, Naik TJ, Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617–30. https://doi.org/10.1172/jci72931.

32. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42. https://doi.org/10.1038/nm.2919.

33. Dhingra R, Margulets V, Chowdhury SR, Thiliveris J, Jassal D, Fernyhough P, Dorn GW 2nd, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci U S A. 2014;111(51):E5537–44. https://doi.org/10.1073/pnas.1414655111.

34. Ostatpan N, Prohmmitikut A, Chattipakorn SC, Chattipakorn N. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: insights
for future interventions. J Cell Mol Med. 2020;24(12):6534–57. https://doi.org/10.1111/jcmm.15305.

39. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–80. https://doi.org/10.1016/j.jacc.2021.12.011.

40. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. https://doi.org/10.1161/CIR.000000000010016.

41. Hiona A, Lee AS, Nagendra J, Xie X, Conolly AJ, Robbins RC, Wu JC. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142(2):396–403.e3. https://doi.org/10.1016/j.jtcvs.2010.07.097.

42. Cardinale D, Colombo A, Sandri MT, Lamanita G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81. https://doi.org/10.1161/circulationaha.106.635144.

43. Kawabata H, Ryimoto T, Ishikawa K. Effect of beta-blocker on metabolism and contraction of doxorubicin-induced cardiotoxicity in the isolated perfused rabbit heart. Angiology. 2000;51(5):405–13. https://doi.org/10.1111/j.1525-157X.2000.tb00037.x.

44. Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, Bugra Z, Mercanoglu F, Oncul A, Ollaz H. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J. 2014;21(5):509–15. https://doi.org/10.5630/cj.2013.0150.

45. Bosch X, Rovira M, Sitges M, Doménech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left Ventricular dysfunction with Enalapril and carvedilol in hemopathies). J Am Coll Cardiol. 2013;61(23):2355–62. https://doi.org/10.1016/j.jacc.2013.02.072.

46. Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, Malhotra P, Jain S. Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res. 2016;144(5):725–9. https://doi.org/10.4103/0971-4122.132314.

47. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62. https://doi.org/10.1016/j.jacc.2006.07.052.

48. de Tassigny A, Assaly R, Schaller S, Pruss RM, Berdeaux A, Morin D. Mitochondrial translocator protein (TSPO) ligands prevent doxorubicin-induced mechanical dysfunction and cell death in isolated cardiomyocytes. Mitochondrion. 2013;13(6):688–97. https://doi.org/10.1016/j.mito.2013.10.001.

49. Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slootan H, Tanis BC, Bruning T, Bax JJ, Ritsema van Eck HJ, de Kam ML, Cohen AF, Mituzhima Y, Burggraaf J. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients. Br J Clin Pharmacol. 2014;78(5):950–60. https://doi.org/10.1111/bcp.12429.

50. Yeh ET, Chang HM. Oncocardiology-past, present, and future: a review. JAMA Cardiol. 2016;1(9):1066–72. https://doi.org/10.1001/jamacardio.2016.2132.

51. Hasinoff BB, Herman EH. Dexrazoxane: how it works in cardiac and tumor cells. Is it a produg or is it a drug? Cardiovasc Toxicol. 2007;7(2):140–4. https://doi.org/10.1007/s12012-007-0023-3.

52. Tebbo CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Conistine LS, Mendenhall NP, Spoto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493–500. https://doi.org/10.1200/jco.2005.02.3879.

53. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spencer D, Jones SE, Wedler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318–32. https://doi.org/10.1200/jco.1997.15.4.1318.

54. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children’s Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854–62. https://doi.org/10.1200/jco.2015.60.8851.

55. Chow EJ, Asselin BL, Schwartz CL, Moody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Conistine LS, Frazier DR, Lipshultz SE, Armenian SH. Late mortality after dexrazoxane treatment: a report from the Children’s Oncology Group. J Clin Oncol. 2015;33(24):2639–45. https://doi.org/10.1200/jco.2014.59.4473.

56. Park J, Choi C. Contribution of mitochondrial network dynamics to intracellular ROS signaling. Commun Integr Biol. 2012;5(1):81–3. https://doi.org/10.4161/cib.18257.

57. Galloway CA, Lee H, Yoon Y. Mitochondrial morphology-emerging role in bioenergetics. Free Radic Biol Med. 2012;53(12):2218–28. https://doi.org/10.1016/j.freeradbiomed.2012.09.035.

58. Faehler K, Gao S, Held M, Posor Y, Haucke V, Noé F, Daumke O. Oligomerization of dynamin superfamily proteins in health and disease. Prog Mol Biol Trans Sci. 2013;117:411–43. https://doi.org/10.1016/b978-0-12-388931-9-00015-5.

59. Rosdah AA, Smiles WJ, Oakhill JS, Scott JW, Langendorf CG, Delbridge LM, Holien JK, Lim SY. New perspectives on the role of Drp1 isoforms in regulating mitochondrial pathophysiology. Pharmacol Ther. 2020;213:107594. https://doi.org/10.1016/j.pharmthera.2020.107594.

60. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872–84. https://doi.org/10.1038/nrm3013.

61. Burman JL, Pickles S, Wang C, Sekine S, Vargas JNS, Zhang Z, Youle AM, Nezich CL, Wu X, Hammer JA, Youle RJ. Mitochondrial fission facilitates the selective mitophagy of protein
aggregates. J Cell Biol. 2017;216(10):3231–47. https://doi.org/10.1083/jcb.201612106.
62. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol. 2007;8(11):870–9. https://doi.org/10.1038/nrm2275.
63. Favaro G, Romanello V, Varanita T, Andrea Desbats M, Morbidoni V, Tezze C, Albiero M, Canato M, Gherardi G, De Stefani D, Mammucari C, Blauw B, Boncompagni S, Protasi F, Reggiani C, Scorrano L, Salvati L, Sandri M. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. Nat Commun. 2019;10(1):2576. https://doi.org/10.1038/s41467-019-10226-9.
64. Prudent J, Zunino R, Sugiura A, Mattie S, Shore GC, McBride HM. MAPL SUMOylation of Drp1 stabilizes an ER/mitochondrial platform required for cell death. Mol Cell. 2015;59(6):941–55. https://doi.org/10.1016/j.molcel.2015.08.001.
65. Lee S, Park YY, Kim SH, Nguyen OT, Yoo YS, Chan GK, Sun X, Cho H. Human mitochondrial Fis1 links to cell cycle regulators at G2/M transition. Cell Mol Life Sci. 2014;71(4):711–25. https://doi.org/10.1007/s00018-013-1428-8.
66. Nakada K, Inoue K, Ono T, Isobe K, Ogura A, Goto YI, Nonaka I, Hayashi JJ. Inter-mitochondrial complementation: mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA. Nat Med. 2001;7(8):934–40. https://doi.org/10.1038/90976.
67. Yang L, Long Q, Liu J, Tang H, Li Y, Bao F, Qin D, Pei D, Liu X. Mitochondrial fusion provides an ‘initial metabolic complementation’ controlled by mtDNA. Cell Mol Life Sci. 2015;72(13):2585–98. https://doi.org/10.1007/s00018-015-1863-9.
68. Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci U S A. 2011;108(25):10190–5. https://doi.org/10.1073/pnas.1011042108.
69. Yao Y, Chu Y, Xu B, Hu Q, Song Q. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019;39(6):BSR20190288. https://doi.org/10.1042/bsr20190288.
70. Han P, Ren X, Xu X, Meng Y. The regulatory mechanisms of dynamin-related protein 1 in tumor development and therapy. Cancer Biother Radiopharm. 2021;36(1):10–7. https://doi.org/10.1080/10565107.2020.179719.
71. Kumar S, Ashraf R, CK A. Mitochondrial dynamics regulators: implications for therapeutic intervention in cancer. Cell Biol Toxicol. 2021. https://doi.org/10.1007/10565-021-09962-5.
72. Xie LL, Shi F, Tan Z, Li Y, Bode AM, Cao Y. Mitochondrial network structure homeostasis and cell death. Cancer. 2018;109(12):3686–94. https://doi.org/10.1111/cas.13830.
73. Ma Y, Wang L, Jia R. The role of mitochondrial dynamics in human cancers. Am J Cancer Res. 2020;10(5):1278–93.
74. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb J. 2012;26(5):2175–86. https://doi.org/10.1096/fj.11-196543.
75. Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q, Yu JR. Anti-tumor effects of Mn2 in gastric cancer. Int J Mol Sci. 2015;14(7):13005–21. https://doi.org/10.3390/ijms140713005.
76. Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, Abel PW, Tu Y. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32(40):4814–24. https://doi.org/10.1038/onc.2012.494.
77. Inoue-Yamauchi A, Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem Biophys Res Commun. 2012;421(1):81–5. https://doi.org/10.1016/j.bbrc.2012.03.118.
78. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, Nunnari J. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008;14(2):193–204. https://doi.org/10.1016/j.devcel.2007.11.019.
79. Qian W, Salamoun J, Wang J, Roginskaya V, Van Houten B, Wipi P. The combination of thioxohydroquinazolines and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. Bioorg Med Chem Lett. 2015;25(4):856–63. https://doi.org/10.1016/j.bmcl.2014.12.072.
80. Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, Llambi F, Green DR, Van Houten B. Novel combination of mitochondrial division inhibitor 1 (mdvi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget. 2014;5(12):4180–94. https://doi.org/10.18632/oncotarget.19444.
81. Suzuki-Karasaki Y, Fujiwara K, Saito K, Suzuki-Karasaki M, Ochiai T, Soma M. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization. Oncotarget. 2015;6(25):21572–88. https://doi.org/10.18632/oncotarget.4268.
82. Wang J, Li J, Santana-Santos L, Shuda M, Sobol RW, Van Houten B, Qian W. A novel strategy for targeted killing of tumor cells: induction of multipolar ac罗斯osomal mitotic spindles with a quinazolinone derivative mdvi-1. Mol Oncol. 2015;9(2):488–502. https://doi.org/10.1016/j.molonc.2014.10.002.
83. Kou P, Liu L, Zheng LD, Payne KK, Manjili MH, Idowu MO, Zhang J, Schmelz EM, Cheng Z. Coordinated upregulation of mitochondrial biogenesis and autophagy in breast cancer cells: the role of dynamin related protein-1 and implication for breast cancer treatment. Oxid Med Cell Longev. 2016;2016:4085727. https://doi.org/10.1155/2016/4085727.
84. Zhou D, Ren K, Wang M, Wang J, Li E, Hou C, Su Y, Jin Y, Zou Q, Zhou P, Liu X. Long non-coding RNA RACGAP1P1 promotes breast cancer invasion and metastasis via miR-345-5p/RACGAP1-mediated mitochondrial fission. Mol Oncol. 2021;15(2):543–59. https://doi.org/10.1016/j.molonc.2021.02.016.
85. Han Y, Kim B, Cho U, Park IS, Kim SI, Dhanasekaran DN, Tsang BK, Song YS. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene. 2019;38(45):7089–105. https://doi.org/10.1038/s41388-019-0949-5.
86. Woo SM, Min KJ, Kwon TK. Inhibition of Drp1 sensitizes cancer cells to cisplatin-induced apoptosis through transcriptional inhibition of c-FLIP expression. Molecules. 2020;25(24):5793. https://doi.org/10.3390/molecules25245793.
87. Ma M, Lin XH, Liu HH, Zhang R, Chen RX. Suppression of DRP1-mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy. Oncol Rep. 2020;43(3):1010–8. https://doi.org/10.3892/or.2020.7476.
88. Akita M, Suzuki-Karasaki M, Fujiwara K, Nakagawa C, Soma M, Yoshida Y, Ochiai T, Tokuhashi Y, Suzuki-Karasaki Y. Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis. Int J Oncol. 2014;45(5):1901–12. https://doi.org/10.3892/ijoi.2014.2608.
89. Courtois S, de Luxán-Delgado B, Penin-Peyta L, Royo-García A, Parejo-Alonso B, Jagust P, Alcalá S, Rubiolo JA, Sánchez L, Sainz B Jr, Heeshen C, Sancho P. Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential. Cancers (Basel). 2021;13(4):698. https://doi.org/10.3390/cancers13040698.
103. Gharaeei M, Hussain A, Janneh O, Maddock H. Attenuation of doxorubicin-induced cardiotoxicity by mdvi-1: a mitochondrial division/mitophagy inhibitor. PLoS One. 2013;8(10):e77713. https://doi.org/10.1371/journal.pone.0077713.

104. Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, Yang X, Zou Y, Sun A, Qian J, Ge J. LC3β96 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138–48. https://doi.org/10.1016/j.yjmcc.2017.06.003.

105. Zhuang X, Sun X, Zhou H, Zhang S, Zhong X, Xu X, Guo Y, Xiong Z, Liu M, Lin Y, Zhang M, Liao X. Klotho attenuated doxorubicin-induced cardiomyopathy by alleviating dynamin-related protein 1-mediated mitochondrial dysfunction. Mech Ageing Dev. 2021;195:111442. https://doi.org/10.1016/j.mad.2021.111442.

106. Qin Y, Lv C, Zhang X, Ruan W, Xu X, Chen C, Ji X, Lu L, Guo X. Neuraminidase1 inhibitor protects against doxorubicin-induced cardiotoxicity via suppressing Drp1-dependent mitophagy. Front Cell Dev Biol. 2021;9:802502. https://doi.org/10.3389/fcell.2021.802502.

107. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012–22. https://doi.org/10.1161/circulationaha.109.906610.

108. Sharp WW, Fang YH, Han M, Zhang HJ, Hong Z, Banathy A, Morrow E, Ryan JJ, Archer SL. Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. Faseb j. 2014;28(1):316–26. https://doi.org/10.1096/fj.12-26225.

109. Rosdah AA, Holien JK, Delbridge LMD, Dustin JJ, Lim SY. Mitochondrial fission - a drug target for cytoprotection or cytodestruction? Pharmacol Res Perspect. 2016;4(3):e00235. https://doi.org/10.1002/prp2.235.

110. Liang X, Wang S, Wang L, Ceylan AF, Ren J, Zhang Y. Mitophagy inhibitor liensin suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission. Pharmacol Res. 2020;157:104846. https://doi.org/10.1016/j.phrs.2020.104846.

111. Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouliad MA, Ghosh S, Shim W, Brunham LR. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci Rep. 2016;6:25333. https://doi.org/10.1038/srep25333.

112. Golforoush PA, Narasimhan P, Chaves-Guerrero PP, Lawrence E, Newton G, Yan R, Harding SE, Perrier T, Chapman KL, Schneider MD. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4. Sci Rep. 2020;10(1):12060. https://doi.org/10.1038/s41598-020-68907-1.

113. Schwach V, Slaats RH, Passier R. Human pluripotent stem cell-derived cardiomyocytes for assessment of anticancer drug-induced cardiotoxicity. Front Cardiovasc Med. 2020;7:50. https://doi.org/10.3389/fcvm.2020.00050.

114. Cui N, Wu F, Lu WJ, Bai R, Ke B, Liu T, Li L, Lan F, Cui M. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes. J Cell Mol Med. 2019;23(7):4627–39. https://doi.org/10.1007/s12197-019-04136-1.

115. Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, Holmström A, Chang AC, Coronado MJ, Ebert AD, Knowles JW, Telli ML, Witteles RM, Blau HM, Bernstein D, Altman RB, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22(5):547–56. https://doi.org/10.1038/nm.4087.
116. Ueno M, Kakinuma Y, Yuki K, Murakoshi N, Iemitsu M, Miyauchi T, Yamaguichi I. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci. 2006;101(2):151–8. https://doi.org/10.1254/jphs.fp0050980.

117. Wang S, Song P, Zou MH. Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem. 2012;287(11):8001–12. https://doi.org/10.1074/jbc.M111.315812.

118. Cappetta D, Rossi F, Piegari E, Quaini F, Berrino L, Urbanek K, De Angelis A. Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res. 2018;127:4–14. https://doi.org/10.1016/j.phrs.2017.03.016.

119. Zhan H, Aizawa K, Sun J, Tomida S, Otsu K, Conway SJ, McKinnon PJ, Manabe I, Komuro I, Miyagawa K, Nagai R, Suzuki T. Ataxia telangiectasia mutated in cardiac fibroblasts diminishes aberrant mitochondrial fission and neurotoxicity. J Biol Chem. 2016;291(1):583–594.e6. https://doi.org/10.1016/j.jbc.2015.12.008.

120. Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE. A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence. Oncotarget. 2016;7(45):72243–57. https://doi.org/10.18632/oncotarget.12494.

121. Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276(50):47266–76. https://doi.org/10.1074/jbc.M106829200.

122. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem. 2000;275(43):33585–92. https://doi.org/10.1074/jbc.M003890200.

123. Wojcik T, Buczek E, Majzner K, Kolodziejczyk A, Miszczyk J, Kacza P, Kwiak T, Baranska M, Szymonski M, Chlopicki S. Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells. Toxicol In Vitro. 2015;29(3):512–21. https://doi.org/10.1016/j.tiv.2014.12.009.

124. Bielak-Zmijewska A, Wnuk M, Przybylska D, Grabowska W, Lewinska A, Altser O, Korwek Z, Cmoch A, Myszka A, Pikula S, Mosieniak G, Sikora E. A comparison of replicative senescence and doxorubicin-induced premature senescence of vascular smooth muscle cells isolated from human aorta. Biogerontology. 2014;15(1):47–64. https://doi.org/10.1007/s10522-013-9477-9.

125. Verheijen M, Schroders Y, Gmuender H, Nudischer R, Clayton O, Hynes J, Niederer S, Cordes H, Kuepfer L, Kleinjans J, Caiment F. Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018;294:184–92. https://doi.org/10.1016/j.toxlet.2018.05.029.

126. Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Trettler L, Adam-Vizi V, Cherok E, Khalil A, Yadava N, Ge SX, Francis TC, Kennedy NW, Picton LK, Kumar T, Uppuluri S, Miller AM, Itoh K, Karbowski M, Sasaki H, Hill RB, Polster BM. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40(6):583–594.e6. https://doi.org/10.1016/j.devcel.2017.02.020.

127. Xi Q, Qvit N, Su YC, Molchy-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013;126(PT 3):789–802. https://doi.org/10.1242/jcs.114439.

128. Guo X, Disatnik MH, Monbureau M, Shamloo M, Molchy-Rosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest. 2013;123(12):5371–88. https://doi.org/10.1172/JCI70911.

129. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T, Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10(6):839–50. https://doi.org/10.1016/j.devcel.2006.04.002.

130. Shen F, Gai J, Xing J, Guan J, Fu L, Li Q. Dynasore suppresses proliferation and induces apoptosis of the non-small-cell lung cancer cell line A549. Biochem Biophys Res Commun. 2018;495(1):1158–66. https://doi.org/10.1016/j.bbrc.2017.11.109.

131. Gao D, Zhang L, Dhillon R, Hong TT, Shaw RM, Zhu J. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013;8(4):e60967. https://doi.org/10.1371/journal.pone.0060967.

132. Wu D, Dasgupta A, Chen KH, Neuber-Hess M, Patel J, Hurst TE, Mewburn JD, Lima PDA, Alizadeh E, Martin A, Wells M, Snieckus V, Archer SL. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: therapeutic potential of Drp1 inhibitor and Drp1a in cancer and cardiac ischemia-reperfusion injury. Faseb J. 2020;34(1):1447–64. https://doi.org/10.1096/fj.201901467R.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.